The inventory of extremely specialised healthcare firm DexCom (NASDAQ: DXCM) wasn’t the image of well being on Friday. It misplaced almost 2% of its worth in that day’s buying and selling session, on the again of an earnings launch that raised investor issues about slowing gross sales progress. The S&P 500 index outperformed the inventory, and that is not saying a lot, because it primarily ended the day flat over Thursday.
Slight beats on the highest and backside traces
Reporting its third-quarter outcomes after market hours Thursday, DexCom mentioned its income amounted to $994 million for the interval. This was, nevertheless, solely 2% increased on a year-over-year foundation for the beforehand fast-growing glucose monitoring merchandise specialist. Non-GAAP (adjusted) web revenue fell to barely over $181 million ($0.45 per share) from the year-ago determine of $204 million.
In line with Zack’s, the consensus analyst estimate for profitability was $0.43. In the meantime, DexCom solely marginally topped the typical prognosticator projection for income.
Through the quarter DexCom launched a brand new product, Stelo, a glucose biosensor for grownup sufferers with prediabetes and sort 2 diabetes not at the moment on insulin remedy. The corporate would not hesitate to level out that it is the first such product accessible over-the-counter on this nation. This rollout, plus product launches in Australia and France, was a key driver of that top-line progress.
Modeling at the least 11% income enchancment this 12 months
DexCom proffered steerage for everything of 2024. It is forecasting income of roughly $4 billion to $4.05 billion for the 12 months, which might characterize progress of at the least 11% over the 2023 determine. Its adjusted working margin ought to land at round 20%; the corporate didn’t present extra particular profitability estimates.
On condition that it is a enterprise with a strong product lineup and a compelling new providing (Stelo), traders have been clearly anticipating extra from its third quarter. I do not suppose DexCom is doing badly, however it’ll in all probability have to juice these top-line numbers to be a extra compelling inventory for this discerning market.
Must you make investments $1,000 in DexCom proper now?
Before you purchase inventory in DexCom, think about this:
The Motley Idiot Inventory Advisor analyst crew simply recognized what they imagine are the 10 best stocks for traders to purchase now… and DexCom wasn’t one among them. The ten shares that made the minimize might produce monster returns within the coming years.
Think about when Nvidia made this record on April 15, 2005… in the event you invested $1,000 on the time of our advice, you’d have $860,447!*
Inventory Advisor offers traders with an easy-to-follow blueprint for achievement, together with steerage on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than quadrupled the return of S&P 500 since 2002*.
*Inventory Advisor returns as of October 21, 2024
Eric Volkman has no place in any of the shares talked about. The Motley Idiot recommends DexCom. The Motley Idiot has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
